Private Capital Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Private Capital Group’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-498	Closed	-$8K	–	2516
2019 Q2	$8K	Buy	+498	New	+$4.76K	﹤0.01%	1496
2018 Q4	–	Sell	-140	Closed	-$1K	–	2392
2018 Q3	$1K	Sell	140 -358	-72%	-$5.32K	﹤0.01%	2134
2018 Q2	$7K	Hold	498	–	–	﹤0.01%	1568
2018 Q1	$9K	Buy	498 +3	+0.6%	+$59	﹤0.01%	1429
2017 Q4	$11	Buy	+495	New	+$15.9K	﹤0.01%	1337

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Private Capital Group's FPRX Position: Q3 2019 in Review

Private Capital Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2019, closing a stake of 498 shares — an estimated $8K sold.

Private Capital Group first reported a position in FPRX in Q4 2017 and held it in 5 quarters. The position peaked at $9K in Q1 2018. 103 funds tracked by Wall St. Rank hold FPRX as of Q3 2019.

Private Capital Group reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Private Capital Group sold 498 Five Prime Therapeutics, Inc. shares in Q3 2019, an estimated $8K.
Private Capital Group first reported a position in Five Prime Therapeutics, Inc. in Q4 2017 and held it in 5 quarters.
Private Capital Group's Five Prime Therapeutics, Inc. position peaked at $9K in Q1 2018.
103 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2019.

Based on Private Capital Group's 13F filing for Q3 2019, filed 13 Nov 2019.